LPGAT1-AS1

Across TCGA pan-cancer cohorts, LPGAT1-AS1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of LPGAT1-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where LPGAT1-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LPGAT1-AS1 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

LIHC, KIRP, and BRCA are the cancer types where LPGAT1-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LPGAT1-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+0.087	<.001	8	view →
KIRP	All	All	+0.057	.003	6	view →
BRCA	Female	II,III,IV	+0.050	.001	6	view →
THCA	All	All	−0.039	.017	2	view →
LUAD	All	All	+0.039	.014	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

LPGAT1-AS1–LIHC

Open the LIHC breakdown →